<DOC>
	<DOCNO>NCT01279096</DOCNO>
	<brief_summary>The purpose study determine Maximum Tolerated Dosage ( MTD ) , Dosage Limited Toxicities ( DLT ) , Rate Phase 2 Dosage clofarabine use combination etoposide , asparaginase , mitoxantrone dexamethasone ass feasibility safety combination regimen treat child high risk relapse refractory acute lymphoblastic leukemia ( ALL ) .</brief_summary>
	<brief_title>Safety Clofarabine With Multiagent Chemotherapy Childhood Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>I.3 Primary Objectives : To determine MTD escalate dos clofarabine start 20 mg/m2/day 40 mg/m2/day day 1 day 5 , replacement cytarabine part combination etoposide , asparaginase , mitoxantrone dexamethasone ( VANDA regimen ) . I.4 Secondary Objectives : 1 . To determine safety tolerability clofarabine use combination etoposide , asparaginase , mitoxantrone dexamethasone ( VANDA regimen ) determine duration , seriousness , relationship adverse event occur treatment follow-up period ; search DLT 2 . To determine Overall Response rate ( OR ) ( Complete Remission + Complete Remission without platelet 's normalization ) clofarabine plus etoposide , asparaginase , mitoxantrone dexamethasone ( VANDA regimen ) pediatric patient refractory relapse ALL establish clofarabine RP2D . 3 . To document rate Partial Response [ ] study population 4 . To document time-to-event parameter , include duration remission , Event Free Survival ( EFS ) , 4-month EFS , overall survival ( OS ) .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Recurrence</mesh_term>
	<mesh_term>Dexamethasone acetate</mesh_term>
	<mesh_term>Dexamethasone</mesh_term>
	<mesh_term>Dexamethasone 21-phosphate</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<mesh_term>BB 1101</mesh_term>
	<criteria>1 21 year old date acute lymphoblastic leukemia initial diagnosis Very early medullary first relapse occur first 18th month complete remission OR patient second relapse OR relapse occur 6 month myeloablative stem cell transplantation eligible . Have Karnofsky Performance Status ( KPS ) ≥70 patient &gt; 10 year age Lansky Performance Status ( LPS ) ≥60 patient ≤10 year age . No concomitant malignant disease . No active uncontrolled infection . Have adequate renal hepatic function absence concomitant severe cardiovascular disease , i.e . congestive heart failure Female patient childbearing potential must negative serum pregnancy test within 2 week prior enrollment . Male female patient must use effective contraceptive method study minimum 6 month study treatment . Current concomitant chemotherapy , radiation therapy , immunotherapy specify protocol . Use investigational agent within 30 day . Known hypersensitivity clofarabine excipients . Known hypersensitivity mitoxantrone , etoposide excipients . Allergy E ColiAsparaginase Erwinia Asparaginase Prior transplant le 6 month ago . Trisomy 21 Have severe concurrent disease , history serious organ dysfunction disease involve heart , kidney , liver , organ system may place patient undue risk undergo treatment . Patients systemic fungal , bacterial , viral , infection control ( define exhibit ongoing signs/symptoms related infection without improvement , despite appropriate antibiotic treatment ) . Pregnant lactating patient . Any significant concurrent disease , illness , psychiatric disorder would compromise patient safety compliance , interfere consent , study participation , follow , interpretation study result .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>23 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>Acute lymphoblastic leukemia</keyword>
	<keyword>relapse</keyword>
	<keyword>childhood</keyword>
	<keyword>clofarabine</keyword>
</DOC>